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Do cannabis-based medicinal extracts have general or speciﬁc effects on
symptoms in multiple sclerosis? A double-blind, randomized, placebo-
controlled study on 160 patients
Derick T Wade*, Petra Makela, Philip Robson, Heather House and Cynthia Bateman
Oxford Centre for Enablement, Windmill Road, Oxford OX3 7LD, UK; The Research Centre, Unit G1, The Magdalen
Centre, The Oxford Science Park, Oxford OX4 4GA, UK
The objective was to determine whether a cannabis-based medicinal extract (CBME) benefits a range of symptoms due to multiple
sclerosis (MS). A parallel group, double-blind, randomized, placebo-controlled study was undertaken in three centres, recruiting 160
outpatients with MS experiencing significant problems from at least one of the following: spasticity, spasms, bladder problems, tremor or
pain. The interventions were oromucosal sprays of matched placebo, or whole plant CBME containing equal amounts of delta-9-
tetrahydrocannabinol (THC) and cannabidiol (CBD) at a dose of 2.5/120 mg of each daily, in divided doses. The primary outcome
measure was a Visual Analogue Scale (VAS) score for each patient’s most troublesome symptom. Additional measures included VAS
scores of other symptoms, and measures of disability, cognition, mood, sleep and fatigue. Following CBME the primary symptom score
reduced from mean (SE) 74.36 (11.1) to 48.89 (22.0) following CBME and from 74.31 (12.5) to 54.79 (26.3) following placebo [ns].
Spasticity VAS scores were significantly reduced by CBME (Sativex) in comparison with placebo (P /0.001). There were no significant
adverse effects on cognition or mood and intoxication was generally mild.
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Introduction
Multiple sclerosis (MS) may lead to a wide range of
impairments best managed through individualized inter-
ventions of many types. Complex drug combinations are
sometimes necessary but these are often only partially
effective or associated with unacceptable side effects.
Consequently, drugs that can target several impairments
at the same time are especially useful. For example
amitriptyline may help pain, bladder symptoms, sleep
and depression. Anecdotal animal and clinical data have
all suggested that cannabis or cannabinoids may amelio-
rate pain, spasticity, muscle spasms and other symptoms
in MS.
18 UK doctors have been barred from prescribing
cannabis preparations since 1971 under the Misuse of
Drugs Act. Illicit self-medication has continued
9,10
although hampered by variability in potency of supply
and problems associated with both smoked and oral routes
of delivery.
Cannabis contains more than 60 different oxygen-con-
taining aromatic hydrocarbon compounds unique to the
plant, known as cannabinoids. The principal psychophar-
macological component in cannabis is D9-tetrahydrocan-
nabinol (THC),
11 but other derivatives may have
therapeutic or synergistic potential. Cannabidiol (CBD) is
the most promising of these, especially as it is nonpsy-
choactive and may modulate the intoxicating and/or
memory effects of THC.
12 The majority of cannabis
available illicitly in the UK contains significant amounts
of THC and CBD.
13
Recently, standardized whole plant cannabis medicinal
extracts (CBME) have become available for clinical re-
search. Selective breeding and rigorous analytic proce-
dures during extraction can be used to ensure purity and
stability.
14 The oromucosal route lends itself to self-
titration by the patient and provides a satisfactory
pharmacokinetic profile.
15 Single case crossover studies
have demonstrated that these CBMEs have the potential
to reduce previously intractable symptoms, including
pain, spasms and spasticity in patients with MS and
other neurological conditions
16 with low levels of
intoxication.
Nonetheless the evidence supporting the use of canna-
binoids for symptom relief in MS remains inconclusive,
even after a recently reported trial involving 657 pa-
tients,
17 and concerns about safety have not been re-
solved.
18,19 The current study is one of several designed to
extend earlier work
16 in assessing the efficacy and toler-
ability of an oromucosal combined preparation of THC
and CBD in the amelioration of multiple symptoms
associated with MS.
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This randomized, placebo-controlled, double-blind
parallel group study was conducted at three clinical
centres in the UK with approval of the local research
ethics committees. Patients were recruited through
MS societies and referrals from outpatient clinics or
general practitioners.
To be eligible, patients had to:
. have clinically confirmed MS of any type. This was
undertaken through taking a history, undertaking a full
examination, and full review of all hospital notes;
. have been stable over the preceding four weeks with no
relapse, confirmed clinically on entry to the study;
. be on stable regular medication (i.e., not changed in the
last four weeks);
. be willing to abstain from alternative cannabinoid use
for seven days prior to screening and throughout the
study; and
. volunteer one of the five target symptoms at a sufficient
level of severity (see below).
Following informed consent, patients were screened for
eligibility. This included having one of the chosen five
target symptoms: spasticity, spasms, bladder problems,
tremor or pain that was not obviously musculoskeletal.
Each patient nominated the most troublesome of these as
their primary symptom. Patients were asked to rate the
severity of each target symptom on a Visual Analogue
Scale (VAS) with anchors ‘no problem’ to ‘very bad’.
Patients were excluded if the primary symptom was rated
at less than 50% of maximal severity.
Other exclusion criteria were a current or past history of
drug or alcohol abuse, significant psychiatric illness other
than depression associated with MS, serious cardiovas-
cular disorder, significant renal or hepatic impairment or
history of epilepsy. Patients could not be included if they
had a planned visit abroad during the active study.
Caution was exercised for patients taking drugs metabo-
lized by certain cytochrome P450 enzymes, such as
tricyclic antidepressants and anticonvulsants.
If eligible, patients were asked to consent to British
Home Office notification of their participation, and had an
ECG, and biochemical and haematological tests and (if
appropriate) a pregnancy test.
Then a full assessment battery was undertaken by a
specialist research nurse (see below). Patients were sup-
plied with a run-in diary card of instructions to record
symptoms on a daily basis. Most patients had tried other
drugs for their symptom(s), and they were asked to
continue concomitant medications throughout the study
where possible.
Following the two-week base line period, patients
returned to the study centre for review of eligibility,
including further VAS completion for target symptoms.
If the inclusion criteria were still fulfilled, dosing with
randomized medication was initiated.
Patients were randomized by permuted blocks of size
four, stratified by nominated primary symptom and
centre. The pharmacist at each centre was provided with
a randomization scheme for each primary symptom and
assigned the treatments in sequential patient number
order from the appropriate randomization list.
The study medication was whole plant extract contain-
ing equal proportions of THC and CBD. The CBME
(Sativex) was presented in a pump action spray, delivering
2.7 mg THC and 2.5 mg CBD with each actuation. The
placebo spray contained excipients only. All preparations
incorporated a peppermint flavour and colouring to
disguise the taste and appearance of CBME.
Supervision of the first dose, given in the clinic, was
followed by instructions to titrate slowly during home
dosing, aiming for optimal balance of symptom relief and
unwanted effects. Guidelines were given for increments
up to a maximum of 120 mg THC and 120 mg CBD per day
with no more than 20 mg of each in any 3-hour period.
Patients recorded the time and number of actuations per
day, in a dosing diary. Regular telephone contact was
maintained according to individual patient requirements
and a brief safety visit was conducted after two weeks, to
review dosing and adverse events.
After the six-week double-blind parallel group trial,
patients returned to the study centre for a repeat of the full
assessment battery. This was undertaken by a research
nurse who was not involved in dosing advice and home
contact with that patient, to ensure blinding. The assess-
ments were carried out at the same time of day (morning)
in the same order and by the same nurse for each patient
throughout the trial where possible.
All patients were then offered active medication for a
further four weeks. Retitration was necessary because for
the placebo group this would have been a patient’s first
exposure to active medication.
At the end of this second period, a total of ten weeks
dosing, patients had the opportunity to continue into an
open-label long-term safety and tolerability study. The
findings for the 137 patients who proceeded into the
extension will be reported separately.
The full assessment battery comprised:
. 100 mm VAS for the primary target symptom, and for
any other of the five target symptoms that were
troublesome;
. Barthel Activities of Daily Living (ADL) index,
20 the
Rivermead Mobility Index,
21 the short Orientation-
Memory-Concentration Test,
22 the Adult Memory and
Information Processing Battery test of attention adapted
for patients with MS,
23 the General Health Question-
naire 28,
24 the Guy’s Neurological Disability scale
(GNDS),
25 the Beck Depression Inventory,
26 the Fatigue
Severity Scale
27 and VAS to rate sleep: quality, amount
and feelings on awakening;
. diary records using a VAS of spasm frequency, feeling
of intoxication, and severity of each of the target
symptoms on one nominated day each week;
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Multiple Sclerosisand, where appropriate:
. The modified Ashworth Scale of Spasticity
28 measured
at wrist, elbow, knee and ankle and summed across all
joints (total score /20), a tremor ADL questionnaire,
29
the Nine-Hole Peg Test of manual dexterity,
30 a ques-
tionnaire on disability arising from urinary inconti-
nence
31 and the time in seconds to walk 10 m.
The nominated primary symptom VAS score, henceforth
referred to as the Primary Symptom Score (PSS), was
compared between treatment groups using analysis of
covariance (ANCOVA) with baseline primary symptom
score as the covariate. The adjusted treatment means,
treatment difference and the standard error of the mean
difference (SE), P-value and 95% confidence interval for
the treatment difference were presented. The VAS scores
for each of the five individual primary symptoms and the
sum of all five VAS scores for each patient (known as the
Summed Symptom Score, scoring ‘0’ where the patient
did not experience the symptom) were analysed in the
same way, as were the mean scores from daily diary cards
recorded during the baseline and final two weeks of the
active trial (i.e., weeks 5 and 6).
Power calculations using data from the initial study
16
suggested that a minimum of 65 patients would be needed
to detect a 10% shift in the primary symptom VAS score in
comparison with placebo. Following external advice, a
decision was taken to increase the size of the study in
order to facilitate comparison of individual primary
symptoms.
Multiple statistical comparisons were made, because in
addition to being an RCTwith a primary outcome, this was
also an exploratory study. All P-values presented are for
single comparisons, but readers should be aware that a
Bonferroni correction for multiple comparisons applied to
11 measures would make P /0.0045 the significant value
for a /0.05.
Role of the funding source
GW Pharma Ltd contributed to the study design and was
involved in collection of the data. Data handling and
analysis were contracted by GW Pharma Ltd to an
independent research organization.
Results
Two hundred and seventeen patients were screened, of
whom 160 were found to be eligible for inclusion. The
flow of patients can be seen in Figure 1.
Demographic and baseline data are shown in Table 1;
there were no statistically significant differences between
the groups although the active treatment group was
slightly more disabled (difference in mean Barthel score
1.5/20).
The data from the six-week assessment and the results
of calculating adjusted mean difference scores can be seen
in Table 2 and diary card data for the primary symptoms
are shown in Table 3.
The PSS improved in both groups, with no statistically
significant difference between the groups. However pa-
tients with pain all showed a large effect that was almost
identical in patients on active and on placebo, and when
patients with pain as their primary symptom are removed,
the difference between CBME and placebo becomes
statistically significant (without Bonferroni correction;
P /0.03). Analysis of the summed symptom score gave
similar results (data not shown).
At the end of the double-blind trial (at six weeks),
patients on active treatment whose primary symptom had
been spasticity showed a significant reduction in their
VAS (even after Bonferroni correction; P /0.001) in
comparison with placebo. This was supported by diary
data comparing entries from the baseline and final two
weeks of the active trial (P /0.009).
Although not statistically significant, the 10 m walking
time improved more in the actively treated group, and
greater improvements in VAS scores and in diary data
were also seen for bladder control following CBME
compared with placebo.
A statistically significant treatment difference in favour
of CBME was seen in patients’ assessment of the quality of
sleep (P /0.047), and a difference in favour of the placebo
group was seen in the GNDS scores (P /0.048). There
were no significant differences between the groups on
measures of cognition and mood.
The relative incidence of adverse effects in active and
placebo groups, as submitted to regulatory authorities, is
shown in Table 4.
The average amount of CBME taken over the first ten
weeks in each group is shown in Figure 2, where it can be
seen that patients in both groups increased dosage
gradually, reaching a plateau at about four weeks, with
patients in the placebo group tending to take higher doses.
The graph of intoxication shown in Figure 3 reveals a
slight increase in level of intoxication from baseline at
commencement of the active medication, which appears
to reduce by week ten of dosing.
Discussion
This large, randomized, placebo-controlled trial ambi-
tiously attempted to amalgamate outcome measures of
five MS symptoms into a single PSS. Although the PSS
following CBME reduced by 25.29 mm out of 100 mm and
following placebo reduced by 19.35 mm out of 100 mm,
this was not a statistically significant difference. However,
the difference in spasticity score between CBME and
placebo was statistically significant ( /31.2 versus  /8.4,
P /0.001), and this significance was maintained following
a Bonferroni correction for multiple measures.
The study included patients of all ages with a wide
range of impairments and was not restricted by level of
disability. Only patients who may have had specific
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results should therefore be relevant to most patients with
MS. However there are some weaknesses that need
discussion.
One potential weakness is the combination of scores
from different symptoms as a primary outcome measure.
No tool has been developed to measure the efficacy of an
intervention across a range of MS symptoms, as previously
no intervention has been expected to have such a wide-
ranging effect. Implementation of an identical measure for
each key symptom permitted the creation of the PSS. This
enabled us to use a measure personalized to each
individual patient, a process similar to goal attainment
scaling.
32,33 Although most of the validation of VAS has
been conducted in the measurement of pain,
34 VAS was
felt to be an appropriate measure in the other symptom
groups. It had adequate sensitivity and had been demon-
strated to be an effective measure of subjective endpoints
in the pilot study,
16 but the clinical significance of any
change is unknown. The approach of combining scores
across different symptoms does allow patients to select
their symptoms and might detect any general or multi-
symptom benefits, but it also assumes that each symptom
is equal in terms of responsiveness to cannabis and in
terms of variability, and these assumptions may well not
be true.
Five primary symptoms were studied, and consequently
the number of patients with each individual symptom was
small. The largest primary symptom category was spasti-
city, identified by 39 people. The assumptions were that
the estimate of variability was large enough to encompass
the most variable symptom and that each symptom
category responded in a similar way to the medication.
In retrospect these assumptions were incorrect, especially
for pain, and when patients with pain as their primary
symptom are removed from the analysis of changes in the
PSS, the difference between CBME and placebo becomes
significant (only before Bonferroni adjustment; P /0.03).
The large placebo effect for pain may have been explained
by the patient group recruited, many of whom were self-
referred, had not received regular specialist review and
may not have been treated with licensed neuropathic pain
medications.
There are several minor features that could be criticized.
All patients had the clinical diagnosis of MS confirmed,
but we did not specifically categorize the type of MS
because there is no evidence to support the validity (or
reliability) of categorization and because it is unlikely to
 
 
 
 
 
 
Figure 1 Patient ﬂow diagram.
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Multiple Sclerosispredict responsiveness to symptomatic treatment. Patients
were clinically stable. We did record the level of disability
using well validated measures, but not using the Ex-
panded Disability Status Scale (EDSS) in view of its
limitations. We failed to assess the degree of blinding of
our patients and outcome assessors, but we did make
every effort to ensure blinding. We did not check on
whether patients were taking other forms of cannabis, and
although patients were asked not to change other medica-
tion over the first six weeks, they may have done so. Both
of these variables would have tended to reduce any
differences between placebo and experimental groups.
The patients had no difficulty in adopting a self-
titration dosing regime which took up to four weeks.
This generally enabled optimization of symptom relief at a
dose not associated with troublesome adverse effects.
Dose-limiting effects most commonly noted clinically
were intoxication and excessive reduction in lower limb
tone. Although anticipated with the use of THC-contain-
ing medication, the occurrence of intoxication was un-
predictable due to variation between patients in level of
sensitivity. Subjective experiences ranged from mild
drowsiness and disturbance in attention to disorientation
and a feeling of drunkenness. The experience of excess
tone reduction in ambulatory patients was similar to that
associated with use of other anti-spasticity agents. These
effects were easily resolved with dose reduction and
generally patients could stabilize at an acceptable level,
resulting in few withdrawals.
Local discomfort at the application site with mouth
ulceration in five patients was probably related to the
ethanolic formulation. Oromucosal application was cho-
sen to facilitate quicker and more sensitive titration of the
Table 1 Demographic data
Variable Active group
n /80
Placebo group
n /80
Oxford 46 46
Northampton 15 14
London 19 20
Age years (mean, SD,
range)
51.0 (9.4); 27/74 50.4 (9.3); 27/74
Male:female 33:47 28:52
Previous ‘medicinal’
cannabis
30 32
Previous recreational
cannabis
13 21
Primary symptom:
Spasms 20 18
Spasticity 20 19
Bladder control 15 17
Pain 18 19
Tremor 7 7
Experienced symptom:
Spasms 54 58
Spasticity 72 68
Bladder control 57 62
Pain 40 51
Tremor 26 28
Standardized assessments
Barthel ADL index /20 14.2 (6.1) [n /79] 15.7 (5.4) [n /80]
Rivermead Mobility
Index /15
7.1 (5.0) [n /80] 8.2 (4.6) [n /80]
Ashworth score /20 5.0 (3.7) [n /76] 4.6 (4.4) [n /74]
GNDS /60 20.8 (7.6) [n /74] 21.6 (7.5) [n /75]
SOMC /28 25.0 (3.2) [n /79] 24.5 (4.6) [n /79]
AMIPB number correct
in four minutes
22.4 (8.2) [n /75] 20.9 (8.6) [n /74]
AMIPB: Adult Memory and Information Processing Battery;
SOMC: Short Orientation Memory and Concentration Test.
Table 2 Adjusted mean differences in clinic visit scores over six weeks
Measure Active Placebo Diff. 95% CI for difference SE P-value
PSS  /25.2  /25.29 [n /79]  /19.35 [n /77]  /5.93  /13.52, 1.65 3.84 0.124
Primary symptom: VAS
Spasticity  /31.20 [n /19]  /8.40 [n /18]  /22.79  /35.52,  /10.07 6.26 0.001
Spasms  /26.50 [n /20]  /21.20 [n /18]  /5.3  /19.81, 9.22 7.15 0.464
Bladder  /34.32 [n /15]  /26.34 [n /17]  /7.98  /27.44, 11.48 9.51 0.408
Pain  /11.44 [n /18]  /20.17 [n /18] 8.73  /10.39, 27.84 9.4 0.360
Tremor  /21.42 [n /7]  /25.17 [n /6] 3.75  /30.17, 37.68 15.22 0.810
Ashworth  /0.37 [n /73]  /0.59 [n /70] 0.22  /0.50, 0.94 0.365 0.548
GNDS  /0.93 [n /66]  /2.74 [n /63]  /1.81  /0.02, 3.60 0.91 0.048
GHQ total  /2.02 [n /79]  /2.74 [n /75]  /0.72  /2.38, 3.82 1.57 0.647
Fatigue Severity Scale  /0.26 [n /78]  /0.14 [n /76]  /0.12  /0.43, 0.18 0.15 0.427
Barthel ADL index  /0.38 [n /78] 0.09 [n /77]  /0.47  /1.01, 0.07 0.27 0.087
BDI  /2.14 [n /78]  /2.83 [n /77] 0.69  /1.11, 2.50 0.91 0.450
AMIPB 1.90 [n /73] 2.01 [n /70]  /0.11  /1.85, 1.64 0.88 0.904
Bladder questionnaire  /2.03 [n /58]  /1.92 [n /60]  /0.12  /1.77, 1.54 0.83 0.889
10 m time (s)  /2.78 [n /38]  /0.74 [n /47]  /2.35  /5.16, 0.46 1.41 0.070*
NHPT both (s)  /0.47 [n /66]  /0.38 [n /65]  /0.52  /1.58, 0.55 0.54 0.162*
VAS scales:
Quality of sleep  /16.69 [n /79]  /9.60 [n /77]  /7.10  /14.11,  /0.08 3.55 0.047
How much sleep  /13.93 [n /79]  /9.40 [n /77]  /4.53  /11.45, 2.40 3.50 0.198
Feeling upon waking  /9.56 [n /79]  /8.20 [n /77]  /1.36  /8.80, 6.07 3.76 0.717
*Wilcoxon rank sum test, as results not normally distributed; AMIPB: Adult Memory and Information Processing Battery; BDI: Beck
Depression Inventory; CI: confidence intervals; GHQ: General Health Questionnaire; NHPT: Nine-Hole Peg Test; SE: standard error of the
mean difference; SOMC: Short Orientation Memory and Concentration Test.
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Multiple Sclerosismedicine. Less irritant delivery mechanisms are now
being developed.
This study should be viewed in parallel to the other
large study recently published (the CAMS study).
17 The
studies share many outcome measures including the
Ashworth score, the Rivermead Mobility Index, the 10 m
timed walk, the Barthel ADL index and the Guy’s
Neurological Disability Scale (although it was named the
UK neurological disability scale in the CAMS study).
Consequently, meta-analysis may be possible, accepting
that the specific cannabis preparations were different. The
patients in the CAMS study also covered a wide range of
disability, though generally appear to have been more
disabled than our study population. The placebo response
was also quite large, and changes seen in the disability
scales were similarly small.
The CAMS study primarily investigated spasticity,
where it found little measurable benefit in the primary
outcome (the Ashworth scale). However it also reported
patient-assessed changes in four symptoms which were
examined in our study; pain, spasticity, tremor and
bladder control. As with our study, significant subjective
improvements in spasticity were recorded, but in marked
contrast to our study significant improvements in pain
were also noted. There was a strong trend towards a
benefit for tremor in their large sample of 365 patients,
which was not apparent in our small subgroup of 13
patients. Finally they noted no significant effect on
bladder symptoms, which is consistent with our findings.
Given the relatively small number of patients with
particular symptoms, and the large number of compar-
isons made, it is essential that all trends and apparent
differences are viewed cautiously. For example patients in
Table 3 Individual symptom VAS scores identiﬁed as primary as recorded on diary card; change between baseline two weeks and ﬁnal
two weeks
Measure Active Placebo Diff. 95% CI for difference Standard error P-value
Primary symptom:
Spasticity  /17.00 1.42  /18.4  /31.81,  /5.01 6.59 0.009
Spasm frequency  /21.41  /20.14  /1.27  /16.85, 14.31 7.67 0.869
Spasm severity  /21.67  /21.59  /0.08  /17.28, 17.11 8.42 0.992
Bladder  /24.39  /11.10  /13.3  /29.10, 2.52 7.73 0.096
Pain  /9.83  /19.87 10.04  /7.14, 27.22 8.45 0.243
Tremor  /9.20  /5.12  /4.07  /42.06, 33.91 16.79 0.814
Figure 2 Mean number of actuations (9 /SE) per day.
Table 4 Summary of treatment-related adverse events with
greater than 4% incidence
Adverse event Active / n (%) Placebo / n (%)
n 80 80
Dizziness 26 (32.5) 10 (12.5)
Disturbance in attention 7 (8.8) 0 (0)
Headache 7 (8.8) 13 (16.3)
Fatigue 12 (15) 3 (3.8)
Somnolence 7 (8.8) 1 (1.3)
Disorientation 6 (7.5) 0 (0)
Feeling drunk 4 (5) 0 (0)
Vertigo 5 (6.3) 0 (0)
Application site discomfort 21 (26) 18 (22.5)
Nausea 7 (8.8) 5 (6.3)
Diarrhoea 6 (7.5) 2 (2.5)
Mouth ulceration 4 (5) 1 (1.3)
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Multiple Sclerosisthe placebo group appear to improve on the Guy’s
Neurological Disability scale more than patients on
CBME, but the reverse is true for the Barthel ADL index.
Consequently all differences in such items as sleep
quality, bladder control, spasms and fatigue should
be taken as possible indicators for future research, but
no more.
In conclusion, the results of this study suggest that
CBME (Sativex) is an effective treatment for spasticity
associated with MS. The use of gradual self-titration of the
dose allowed most people to achieve benefit without
unduly troublesome side effects. Taking into account the
results of the CAMS trial and our own preliminary study it
is evident that further studies to clarify the precise role
of CBME for people with MS are indicated, especially
its potential for controlling several symptoms at the
same time.
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